--- a
+++ b/clusters/9knumclustersv2/clust_1096.txt
@@ -0,0 +1,90 @@
+Severe sickle cell disease [Hemoglobin SS (Hb SS), Hemoglobin SC (Hb SC) or Hemoglobin SBeta thalassemia (Hb S?) genotype] with at least  of the following manifestations (a-e):
+Hemoglobin (Hb) >  g/dL within  weeks prior to study registration
+Hemoglobin (Hb) >  g/dL
+Hemoglobin (Hb) >  g/dL
+Hemoglobin (Hb) greater than or equal to . g/dL
+Hemoglobin (Hb) concentration < . g/dL
+Adequate bone marrow function (hemoglobin [Hb] ? . g/dL [subjects may be transfused to Hb ? . g/dL]; platelets ?   cells/L; absolute neutrophil count [ANC] ? .   cells/L without the use of hematopoietic growth factors).
+Hemoglobin (Hb) >=  g/dL
+Hemoglobin (Hb) value >  g/dL
+Hb < g/L (<. g/dl) and/or transfusion dependency
+Hemoglobin (Hb) >  g/dL
+Hemoglobin (Hb) > . g/dL
+Hemoglobin (Hb) >=  g/dL
+Hemoglobin (Hb) ? 
+Hemoglobin (Hb) >  g/dL
+Hemoglobin (Hb) at least . grams per deciliter (g/dL) at baseline (blood transfusions are allowed during the screening period to correct Hb values less than . g/dL).
+Hemoglobin (Hb) at least  g/dL (or . mmol/L) at baseline (blood transfusions, hematopoietic growth factors and hematinics are not allowed during the  days prior to screening to correct Hb values less than  g/dL)
+Hemoglobin (Hb) >  g/dl
+Hemoglobin (Hb) < . g/dL
+Hemoglobin (Hb) >= . g/dL
+(For both cohorts A and B): Hemoglobin (Hb) >  G/dL
+Hemoglobin (Hb) ?. and ?. g/dL during screening
+Hemoglobin (Hb) >  g/dL
+Hemoglobin (Hb) > . g/dL within  days prior to enrollment; Note: the use of transfusion or other intervention to achieve Hb >= . g/dL is acceptable
+Hemoglobin (Hb) >  g/dl
+Hemoglobin (Hb) level <  gm/dl
+Hemoglobin (Hb) ?  g/dL
+Hemoglobin (Hb) >=  g/dL
+Hemoglobin (Hb) <  g/dL
+Hemoglobin (Hb) >  g/dL
+Hemoglobin (Hb) ?  g/dL
+Hemoglobin (Hb) >= . mmol/L
+Hemoglobin (Hb) level <  g/dL
+Hemoglobin (Hb) >= . g/dL (transfusion independent)
+Hemoglobin (Hb) >  g/dL
+Hemoglobin (Hb) >= . g/dL
+Hemoglobin (Hb) >=  g/dL (independent of transfusion and/or growth factors within  months prior to cycle  day )
+Hemoglobin (Hb) >  g/dL
+Eligible diagnoses: patients with sickle cell anemia such as sickle cell anemia (hemoglobin [Hb] SS), Hb S/ beta thalassemia, Hb S/beta positive (+) thalassemia, Hb SC disease, Hb SE disease, Hb SD disease, Hemoglobin SO-Arab disease Hb S/hereditary persistence of fetal hemoglobin; other significant hemoglobinopathies that also fulfills a criterion from below
+Hemoglobin (Hb) ?  g/dL
+Hemoglobin (Hb) >=  g/dL
+Hemoglobin (Hb) >=  g/dl
+Hemoglobin (Hb) >=  g/dL
+Hemoglobin (Hb) > . g/dL
+Hemoglobin (Hb) at least  g/dL at baseline (blood transfusions are allowed during the screening period to correct Hb values less than  g/dL)
+Hemoglobin (Hb) >=  g/dL
+Hemoglobin (Hb) >  g/dL
+Hemoglobin (Hb) >= . g/dl
+DONOR: Anemia (hemoglobin [Hb] <  gm/dl) or thrombocytopenia (< ,/ul)
+Polycythemia Vera ( major criteria required)\r\n* Hemoglobin (Hb) > .g/dl (male) or .g/dl (female) or \r\n* Hematocrit (HCT) >  percentile reference range or \r\n* Elevated red cell mass (> % above mean predicted value) or \r\n* Hb > g/dl (male) or g/dl (female) if associated with a sustained rise from baseline with no apparent cause (e.g. treated iron deficiency)\r\n* Presence of JAKVF
+Hemoglobin (Hb) >=  g/dl for males and >=  g/dl for females
+Hemoglobin (Hb) < g/dL (g/L)
+Hemoglobin (Hb) greater than or equal to . g/dL
+Hemoglobin (Hb) >  g/dL
+Hemoglobin (Hb) >  gm/l
+Hemoglobin (Hb) >  g/dl
+Hemoglobin (Hb) > . g/dL within  days prior to enrollment; note: the use of transfusion or other intervention to achieve Hb >=  g/dL is acceptable (within  days prior to registration)
+Hemoglobin (Hb) >=  g/dL without transfusion for  weeks
+Hemoglobin (Hb) <  g/dL
+Hemoglobin (Hb) >  g/dL
+Hemoglobin (Hb) >=  g/dL
+Hb level ? g/dL
+Hemoglobin (Hb) >  g/dL
+Hemoglobin (Hb) greater than or equal . g/dL
+Hemoglobin (Hb) >=  g/dl
+Hemoglobin (Hb) >  g/dL
+Hemoglobin (Hb) >  g/dL
+Hemoglobin (Hb) >=  mg/dl
+Hemoglobin (Hb) > g/dL
+MATCHED RELATED DONOR: Anemia (hemoglobin [Hb] <  gm/dl) or thrombocytopenia (< ,/ul)
+Hemoglobin (Hb) at least  g/dL (or . mmol/L) at baseline (blood transfusions, hematopoietic growth factors and hematinics are not allowed during the  days prior to screening to correct Hb values less than  g/dL)
+Anemia (hemoglobin [Hb] <  g/L)
+Hemoglobin (Hb) >  g/dL
+Hemoglobin (Hb) >=  g/dL
+Hemoglobin (Hb) >=  g/dL
+Hemoglobin (Hb) <  g/dL
+Hemoglobin (Hb) ?  g/dL
+Platelets ?  x ^, Hb ?  g/L, ANC ? . x ^/L.
+Hemoglobin (Hb) level <  gm/dl
+Hemoglobin (Hb) >  gr/dL not supported by transfusions
+Hemoglobin (Hb) >  g/dL
+Hemoglobin (Hb) greater than or equal to g/dL at baseline (blood transfusions,hematopoietic growth factors and hematinics are allowed during the Prerandomization Phase to correct Hb values less than g/dL).
+Hemoglobin (Hb) >=  g/dL
+Hemoglobin (Hb) >  g/dL
+Hemoglobin (Hb)  >= g/dl
+Severe anemia (hemoglobin [Hb] < g/L) if documented in the last month and not corrected prior to study enrollment
+Hemoglobin (Hb) >  g/dL
+Hemoglobin (Hb) >  g/dL
+Hemoglobin (Hb) >  g/dL
+Patients must have >= . g/dL hemoglobin (Hb) and no blood transfusion in the past  days to receive veliparib